Morgan Stanley Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)


Morgan Stanley analyst David Lewis maintained a Buy rating on Zimmer Biomet Holdings (ZBH) today and set a price target of $143. The company’s shares closed on Friday at $125.41.

According to TipRanks.com, Lewis is a 5-star analyst with an average return of 11.6% and a 73.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Baxter International, Edwards Lifesciences, and Irhythm Technologies.

Zimmer Biomet Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $128.67.

See today’s analyst top recommended stocks >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.07 billion and GAAP net loss of $901 million. In comparison, last year the company had a net profit of $1.26 billion.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZBH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts